Glaucoma News and Research

Latest Glaucoma News and Research

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Diopsys develops new SD-OCT imaging software for ophthalmologists

Diopsys, today announced the development of software that uses existing Spectral Domain Optical Coherence Tomography images to assist ophthalmologists and optometrists in diagnosing retinal and optic nerve disease such as glaucoma.

21 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

An independent, national survey reveals 40 percent of consumers prefer to shop for and purchase vision correction services during evenings or weekends.

15 Dec 2010

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.

14 Dec 2010

Ameco Medical to commence clinical trials for PNT procedure's reimbursement approval

Sunridge International, announced today that Ameco Medical is preparing to start the short term clinical trials needed for reimbursement approval.

9 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D3, a mimetic of nerve growth factor (NGF), in a Phase II clinical trial in patients with moderate to severe dry eye disease. MIM-D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production.

22 Nov 2010

AAO to recognize UH optometry dean with Charles F. Prentice Medal Award

Earl L. Smith III, O.D., dean of the College of Optometry and Greeman-Petty Professor at the University of Houston, is the 2010 recipient of the Charles F. Prentice Medal Award from the American Academy of Optometry.

19 Nov 2010

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted the Company three years of marketing exclusivity for BROMDAY (bromfenac ophthalmic solution) 0.09%, as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act.

18 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.

10 Nov 2010

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.

8 Nov 2010

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Global health crises like the recent cholera outbreak in Haiti emphasize the need for new ways to prevent deadly diseases from becoming widespread in developing countries. International experts and scientists will present research ranging from developing a freeze-dried cholera vaccine to new methods of delivering medicines to underserved populations at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 13-18.

4 Nov 2010

Glaucoma News and Research

Latest Glaucoma News and Research

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

FDA approves Novartis' Amturnide for treatment of high blood pressure

Diopsys develops new SD-OCT imaging software for ophthalmologists

NextGen Healthcare announces partnership with Wills Eye for meaningful use

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

Ameco Medical to commence clinical trials for PNT procedure's reimbursement approval

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

Closer to restoring vision loss due to optic nerve damage

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease

AAO to recognize UH optometry dean with Charles F. Prentice Medal Award

FDA grants three years of marketing exclusivity to ISTA's BROMDAY

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in